Evidence map›Paper›PMID 41921839›Full record

ArticleJournal of controlled release : official journal of the Controlled Release Society2026

A versatile capsule-intravaginal ring platform enables rapid and sustained release of monoclonal antibodies for non-hormonal contraception.

Keiichiro Kushiro, Morgan McSweeney, Scott Hammers, David Quan, Yong Zhu, Haley B Flowers, Lauren Dawson, Jinping Yang, Gengi Kleto, Cynthia Cabrales and 6 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of controlled release : official journal of the Controlled Release Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Keiichiro KushiroMucommune, LLC, Morrisville, NC 27560, USA. Electronic address: kushiro@mucommune.com.
Morgan McSweeneyMucommune, LLC, Morrisville, NC 27560, USA.
Scott HammersMucommune, LLC, Morrisville, NC 27560, USA.
David QuanMucommune, LLC, Morrisville, NC 27560, USA.
Yong ZhuDepartment of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Haley B FlowersDepartment of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Lauren DawsonDepartment of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Jinping YangDepartment of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Gengi KletoDepartment of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Cynthia CabralesDepartment of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Alison SchaeferDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599, USA; Department of Microbiology & Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Katherine GibbMucommune, LLC, Morrisville, NC 27560, USA.
Richard ConeMucommune, LLC, Morrisville, NC 27560, USA.
Thomas MoenchMucommune, LLC, Morrisville, NC 27560, USA.
Kathleen L VincentDepartment of Obstetrics and Gynecology, University of Texas Medical Branch, Galveston, TX 77555, USA.
Samuel K LaiDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina-Chapel Hill, Chapel Hill, NC 27599, USA; Department of Microbiology & Immunology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address: lai@unc.edu.

Funding

Next Generation Multipurpose Prevention Technology: An Intravaginal Ring for HIV Prevention and Nonhormonal ContraceptionR01HD101344 · NICHD · OAK CREST INSTITUTE OF SCIENCE · PI BAUM, MARC MICHAEL, LAI, SAMUEL · 2020 to 2024
$3.7M
IND‐enabling development of MM‐008 IVR, an antibody-based nonhormonal contraceptive intravaginal ringR44HD107824 · NICHD · MUCOMMUNE, LLC · PI CONE, RICHARD · 2022 to 2023
$2.1M
Engineering bispecific antibodies for non-hormonal contraceptionR01HD101562 · NICHD · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LAI, SAMUEL · 2020 to 2023
$2.1M
Capsule-intravaginal ring for sustained release of antibodies for non-hormonal contraception and vaginal protection against HIVR44HD097063 · NICHD · MUCOMMUNE, LLC · PI KUSHIRO, KEIICHIRO · 2018 to 2022
$1.9M
In vivo dose finding for an antibody based nonhormonal contraceptive intravaginal ringR44HD100231 · NICHD · MUCOMMUNE, LLC · PI CONE, RICHARD · 2020 to 2021
$1.7M
Nonhormonal contraceptive intravaginal ring based on high valency anti-sperm antibody constructsR33HD099747 · NICHD · MUCOMMUNE, LLC · PI MOENCH, THOMAS RAY · 2021 to 2023
$1.6M
Sustained release of VRC07 from capsule-intravaginal ring for preventing HIV transmission75N93025C00021 · NIAID · MUCOMMUNE, LLC · PI KUSHIRO, KEIICHIRO · 2025 to 2025
$306k
Non-hormonal contraception based on vaginal delivery of multimeric sperm-binding antibodiesR43HD097941 · NICHD · MUCOMMUNE, LLC · PI CONE, RICHARD · 2019 to 2019
$225k
NIAID NIH HHS 75N93025C00021NICHD NIH HHS R01 HD101344NICHD NIH HHS R01 HD101562NICHD NIH HHS R33 HD099747NICHD NIH HHS R43 HD097941NICHD NIH HHS R44 HD097063NICHD NIH HHS R44 HD100231NICHD NIH HHS R44 HD107824NIH HHS 75N93025C00021
6 · The paper itself

Abstract

Non-hormonal contraceptives that do not require use immediately before or after intercourse would likely meet the reproductive health needs of millions of women. We previously reported the engineering of MM008, a highly multivalent monoclonal antibody with 10 Fabs against a unique human sperm antigen, which agglutinates and prevents sperm from swimming through cervicovaginal mucus to reach eggs. Here, we report the development of a versatile capsule-intravaginal ring (IVR) platform that affords precise tuning of mAb release kinetics, enabling both rapid-on and sustained release of MM008 over 30 days into vaginal fluid simulants in vitro, while fully preserving activity and stability. In vivo, MM008-released from the capsule-IVR agglutinated all human sperm introduced into the sheep vagina within 1 min over a span of at least 21 days, a duration that covers the fertility window for women with menstrual cycles up to ∼39 days. MM008-IVR was safe and well tolerated in sheep. These results support further development of MM008-IVR as a long-acting non-hormonal contraceptive, and highlight the broader potential for the capsule-IVR platform to deliver diverse biologics to reinforce female reproductive health.

Indexed as

Antibodies, MonoclonalContraceptive Devices, FemaleAdministration, IntravaginalAnimalsCapsulesContraceptionDelayed-Action PreparationsDrug LiberationFemaleHumansMaleSheepSpermatozoaVaginaAntibodies, MonoclonalCapsulesDelayed-Action PreparationsAnti-sperm antibodyDrug deliveryFemale reproductive healthSheepVaginal ring

Identifiers

PMID41921839
PMCPMC13427349

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.